Rateb Mahmoud, Gad Ahmed A M, Tohamy Dalia, Elmohamady Mohamed Nagy
Ophthalmology Department, Faculty of Medicine, Assiut University, Asyut, Egypt.
Ophthalmology Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt.
J Ophthalmol. 2022 Mar 28;2022:9212253. doi: 10.1155/2022/9212253. eCollection 2022.
To compare implantable collamer lenses (ICLs) and acrylic implantable phakic contact lenses (IPCLs) in the treatment of myopia in adults, as regards refractive outcome and adverse effects.
Prospective, randomized comparative study with phakic intraocular lenses (IOLs) was carried out for treatment of myopia. Patients were randomized into two groups: one for ICL and the other for IPCL. Preoperative assessments included a full examination, pentacam, endothelial cell count, and biometry. We compared the adverse effects and refractive outcomes between both groups. The study was registered in clinical trials and the registration number is NCT04624035.
Sixty eyes of sixty patients (28 in the ICL group and 32 in the IPCL group) with a follow-up period of 12 months. The mean preoperative spherical equivalent was -12.7 ± 3.4 D and -13.6 ± 4.4 D in the ICL and IPCL groups, respectively (=0.37). The mean postoperative spherical equivalent value was ±0.4 ± 0.2 D and ±0.6 ± 0.1 D in the ICL and IPCL groups, respectively. Uncorrected visual acuity (UCVA) has improved from 1.3 ± 0.06 to 0.15 ± 0.02 Log MAR in the ICL group ( < 0.001) and from 1.3 ± 0.02 to 0.15 ± 0.01 Log MAR in the IPCL group ( < 0.001). The mean endothelial cell count was reduced by 3.3% in the IPCL group and by 3.2% in the IPCL group.
Both ICL and IPCL are effective methods to correct high myopia in adults with no statistically significant differences between the two lenses as regarding adverse effects.
比较可植入式胶原晶状体（ICL）和丙烯酸可植入有晶状体眼接触镜（IPCL）在治疗成人近视方面的屈光效果和不良反应。
对有晶状体眼人工晶状体（IOL）治疗近视进行前瞻性、随机对照研究。患者随机分为两组：一组植入ICL，另一组植入IPCL。术前评估包括全面检查、Pentacam检查、内皮细胞计数和生物测量。我们比较了两组之间的不良反应和屈光效果。该研究已在临床试验中注册，注册号为NCT04624035。
60例患者的60只眼（ICL组28只眼，IPCL组32只眼），随访期为12个月。ICL组和IPCL组术前平均等效球镜度分别为-12.7±3.4D和-13.6±4.4D（P=0.37）。ICL组和IPCL组术后平均等效球镜度分别为±0.4±0.2D和±0.6±0.1D。ICL组未矫正视力（UCVA）从1.3±0.06提高到0.15±0.02 Log MAR（P<0.001），IPCL组从1.3±0.02提高到0.15±0.01 Log MAR（P<0.001）。IPCL组平均内皮细胞计数减少3.3%，ICL组减少3.2%。
ICL和IPCL都是矫正成人高度近视的有效方法，两种晶状体在不良反应方面无统计学显著差异。
